Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kissei Pharmaceutical Co. Ltd.

www.kissei.co.jp

Latest From Kissei Pharmaceutical Co. Ltd.

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH inhibitor market in anemia, while Takeda and Meiji Seika see other important approvals and the first biosimilar teriparatide receives a nod.

Japan Approvals

Japan Approves Biosimilar Teriparatide And Darbepoetin

Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.

Biosimilars Japan

Glenmark Takes On Remogliflozin Infringers In India

Alleged infringers of the patent on remogliflozin are facing legal heat in India from Glenmark, in an ongoing case where copies of the product were apparently offered for sale including via third-party trading sites.

India Intellectual Property

Sawai Eyes Global Position Helped By Growth In Japan And Upsher-Smith – But No Biosimilars

In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.

Japan Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Kissei Pharmaceutical Co. Ltd.
  • Senior Management
  • Mutsuo Kanzawa, Chmn. & CEO
    Yoshio Furihata, Pres. & COO
  • Contact Info
  • Kissei Pharmaceutical Co. Ltd.
    Phone: (81) 263 25 9081
    19-48, Yoshino
    Matsumoto City, 399 8710
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register